REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
ROCKVILLE, Md., Nov. 29, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. RGX-202 is an investigational one-time AAV Therapeutic for Duchenne muscular dystrophy (Duchenne), using the NAV® AAV8 vector to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain as well as a muscle-specific promoter to support a targeted therapy for improved resistance to muscle damage associated with Duchenne.
Related news for (RGNX)
- REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
- REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
- REGENXBIO Announces Presentation at the World Muscle Society
- REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
- REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II